Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults

International Journal of Neuropsychopharmacology

Volumn 15, Issue 3, 2012, Pages 297-307

  Cohen, Martin ^a,b,c   Rasser, Paul E ^a,b,c   Peck, Greg ^b   Carr, Vaughan J ^a,d   Ward, Philip B ^d   Thompson, Paul M ^e   Johnston, Patrick ^f   Baker, Amanda ^a,b,c   Schall, Ulrich ^a,b,c  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cerebellum; magnetic resonance imaging; parametric mapping; psychosis; THC

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS;

ADULT; ARTICLE; BRAIN DEVELOPMENT; CANNABIS ADDICTION; CEREBELLUM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; WHITE MATTER; AGE; CEREBELLUM; COMORBIDITY; DOSE RESPONSE; DRUG EFFECTS; IMAGE PROCESSING; MARIJUANA ABUSE; ORGAN SIZE; PATHOLOGY; YOUNG ADULT;

AGE FACTORS; CANNABIS; CEREBELLUM; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAY MATTER; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; ORGAN SIZE; SCHIZOPHRENIA; WHITE MATTER; YOUNG ADULT;

EID: 84858756074     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571100068X     Document Type: Article

References (50)

1. Andreasen NC, Pierson R (2008). The role of the cerebellum in schizophrenia. Biological Psychiatry 64, 81-88.
2. Atkins M, Mackiewich B (1998). Fully automatic segmentation of the brain in MRI. IEEE Transactions on Medical Imaging 17, 98-107. (Pubitemid 128742013)
3. Australian Institute of Health and Welfare (2008). Australia's Health 2008. Australian Institute of Health and Welfare, Canberra, Australia (http://www.aihw.gov.au/publications/aus/ah08/ah08.pdf).
4. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, et al. (2008). Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophrenia Research 99, 1-6.
5. Bolbecker AR, Mehta CS, Edwards CR, Steinmetz JE, et al. (2009). Eye-blink conditioning deficits indicate temporal processing abnormalities in schizophrenia. Schizophrenia Research 111, 182-191.
6. Borgwardt SJ, McGuire PK, Aston J, Berger G, et al. (2007). Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. British Journal of Psychiatry 191, S69-S75. (Pubitemid 350273192)
7. Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, et al. (2008). Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research 106, 108-114.
8. Cohen M, Solowij N, Carr V (2008). Cannabis, cannabinoids and schizophrenia: integration of the evidence. Australian and New Zealand Journal of Psychiatry 42, 357-368. (Pubitemid 351877209)
9. Copeland J, Swift W (2009). Cannabis use disorder : epidemiology and management. International Review of Psychiatry 21, 96-103.
10. Darke S, Ward J, Hall W, Heather N, Wodak A (1991). The Opiate Treatment Index (OTI) Researcher's Manual. National Drug and Alcohol Research Centre Technical Report Number 11, 1991. Sydney: National Drug and Alcohol Research Centre.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. Arlington, VA: American Psychiatric Publishing Inc.
12. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain : A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318. (Pubitemid 27079604)
13. Gogtay N, Thompson PM (2010). Mapping Gray Matter Development : implications for typical development and vulnerability to psychopathology. Brain and Cognition 72, 6.
14. Grant I, Gonzalez R, Carey CL, Natarajan L, et al. (2003). Non-acute (residual) neurocognitive effects of cannabis use : A meta-analytic study. Journal of the International Neuropsychological Society 9, 679-689. (Pubitemid 36889595)
15. Harkany T, Keimpema E, Barabás K, Mulder J (2008). Endocannabinoid functions controlling neuronal specification during brain development. Molecular and Cellular Endocrinology 286, S84-S90.
16. Harris G, Schlaepfer T, Peng L, Lee S, et al. (1994). Magnetic resonance imaging evaluation of the effects of ageing on grey-white ratio in the human brain. Neuropathology and Applied Neurobiology 20, 290-293. (Pubitemid 24189694)
17. Holmes CJ, Hoge R, Collins L, Woods R, et al. (1998). Enhancement of MR images using registration for signal averaging. Journal of Computer Assisted Tomography 22, 324-333. (Pubitemid 28155214)
18. Ichimiya T, Okubo Y, Suhara T, Sudo Y (2001). Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia. Biological Psychiatry 49, 20-27. (Pubitemid 32332950)
19. Keller A, Castellanos FX, Vaituzis AC, Jeffries NO, et al. (2003). Progressive loss of cerebellar volume in childhood-onset schizophrenia. American Journal of Psychiatry 160, 128-133. (Pubitemid 36042436)
20. Lappin J, Dazzan P, Morgan K, Morgan C, et al. (2007). Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. British Journal of Psychiatry 191, S123-S127. (Pubitemid 350273201)
21. Levitt JJ, McCarley RW, Nestor PG, Petrescu C, et al. (1999). Quantitative volumetric MRI study of the cerebellum and vermis in schizophrenia : clinical and cognitive correlates. American Journal of Psychiatry 156, 1105-1107. (Pubitemid 29302811)
22. MacDonald D, Avis D, Evans AC (1994). Multiple surface identification and matching in magnetic resonance images. In : Robb RA (Ed.), Visualisation in Biomedical Computing. Proceedings of SPIE 2359, 160-169. (http://adsabs.harvard. edu/abs/1994SPIE.2359.160M). Accessed 30 July 2010.
23. Mart?́n-Santos R, Fagundo AB, Crippa JA, Atakan Z, et al. (2010). Neuroimaging in cannabis use : A systematic review of the literature. Psychological Medicine.40. 383-398.
24. Mata I, Perez-Iglesias R, Roiz-Santiañ ez R, Tordesillas-Gutierrez D, et al. (2010). Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Research 1317, 297-304.
25. Mazziotta J, Toga A, Evans A, Fox P, et al. (2001). A probabilistic atlas and reference system for the human brain : International Consortium for Brain Mapping (ICBM). Philosophical Transactions of the Royal Society Series B: Biological Sciences 356, 1293-1322. (Pubitemid 32876067)
26. Medina KL, Nagel BJ, Tapert SF (2010). Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Research 182, 152-159.
27. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
28. Nelson HE, Willison J (1991). The Revised National Adult Reading Test-Test Manual. Windsor, UK: NFER-Nelson.
29. Okugawa G, Nobuhara K, Takase K, Kinoshita T (2007). Cerebellar posterior superior vermis and cognitive cluster scores in drug-naive patients with first-episode schizophrenia. Neuropsychobiology 56, 216-219. (Pubitemid 351567540)
30. Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9, 97-113.
31. Pantelis C, Velakoulis D, McGorry PD, Wodds SJ, et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet, 361, 281-288. (Pubitemid 36126187)
32. Picard H, Amado I, Mouchet-Mages S, Olié J, et al. (2008). The role of the cerebellum in schizophrenia: An update of clinical, cognitive, and functional evidences. Schizophrenia Bulletin 34, 155-172. (Pubitemid 350262281)
33. Rais M, Cahn W, Van Haren N, Schnack H, et al. (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 165, 490-496. (Pubitemid 351694292)
34. Rasser PE, Schall U, Peck G, Cohen M, et al. (2010). Cerebellar grey matter deficits in first-episode schizophrenia mapped using cortical pattern matching. Neuroimage 53, 1175-1180.
35. Schmahmann JD, Doyon J, Toga AW, Petrides M, et al. (2000). MRI Atlas of the Human Cerebellum. San Diego, USA: Academic Press.
36. Schmahmann JD, Smith EE, Eichler FS, Filley CM (2008). Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Annals of the New York Academy of Sciences 1142, 266-309.
37. Sled JG, Zijdenbos AP, Evans AC (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Transactions on Medical Imaging 17, 87-97. (Pubitemid 128742012)
38. Solowij N, Battisti R (2008). The chronic effects of cannabis on memory in humans: A review. Current Drug Abuse Reviews 1, 81-98.
39. Stoodley CJ, Schmahmann JD (2009). Functional topography in the human cerebellum: A meta-analysis. Neuroimage 44, 489-501.
40. Substance Abuse and Mental Health Services Administration (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434.
41. Takahashi T, Wood SJ, Yung AR, Soulsby B, et al. (2009). Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Archives of General Psychiatry 66, 366-376.
42. Thomann PA, Roebel M, Dos Santos V, Bachmann S, et al. (2009). Cerebellar substructures and neurological soft signs in first-episode schizophrenia. Psychiatry Research : Neuroimaging 173, 83-87.
43. Thompson PM, Hayashi KM, Sowell ER, Gogtay N, et al. (2004). Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage 23 (Suppl. 1), S2-S18. (Pubitemid 39421703)
44. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, et al. (2003). Dynamics of gray matter loss in Alzheimer's disease. Journal of Neuroscience 23, 994-1005. (Pubitemid 36206191)
45. Thompson RF, Bao S, Chen L, Cipriano BD, et al. (1997). Associative learning. International Review of Neurobiology 41, 151-189. (Pubitemid 127826225)
46. United Nations Office on Drugs and Crime (2008). Annual Report 2008. (http://www.unodc.org/documents/aboutunodc/AR08-WEB.pdf).
47. Vicente J, Olszewski D, Matias J (2008). Prevalence, patterns and trends of cannabis use among adults in Europe. In : A Cannabis Reader : Global Issues and Local Experiences (pp. 6-26). Lisbon: EMCDDA.
48. Whitford TJ, Grieve SM, Farrow TFD, Gomes L, et al. (2006). Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia : A tensor-based morphometry study. Neuroimage 32, 511-519. (Pubitemid 44164627)
49. Witthaus H, Kaufmann C, Bohner G, Ozgü rdal S, et al. (2009). Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research 173, 163-169.
50. Yucel M, Solowij N, Respondek C, Whittle S, et al. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 65, 694-701. (Pubitemid 351787240)